Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Fuji
Deloitte
Cipla
Dow
Federal Trade Commission
Healthtrust
McKesson
Chubb

Generated: May 20, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 204399

« Back to Dashboard

NDA 204399 describes VOGELXO, which is a drug marketed by Upsher-smith Labs and is included in one NDA. It is available from two suppliers. There are three patents protecting this drug. Additional details are available on the VOGELXO profile page.

The generic ingredient in VOGELXO is testosterone. There are sixty-three drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the testosterone profile page.
Summary for 204399
Tradename:VOGELXO
Applicant:Upsher-smith Labs
Ingredient:testosterone
Patents:3
Therapeutic Class:Hormonal Agents, Stimulant/Replacement/Modifying (Sex Hormones/Modifiers)
Formulation / Manufacturing:see details
Pharmacology for NDA: 204399
Ingredient-typeAndrostanes
Mechanism of ActionAndrogen Receptor Agonists
Medical Subject Heading (MeSH) Categories for 204399
Suppliers and Packaging for NDA: 204399
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
VOGELXO testosterone GEL, METERED;TRANSDERMAL 204399 NDA Upsher-Smith Laboratories, LLC 0245-0871 N 0245-0871-05
VOGELXO testosterone GEL, METERED;TRANSDERMAL 204399 NDA Upsher-Smith Laboratories, LLC 0245-0871 N 0245-0871-35

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:GEL;TRANSDERMALStrength50MG/5GM PACKET
Approval Date:Jun 4, 2014TE:AB2RLD:No
Patent:➤ Sign UpPatent Expiration:Feb 11, 2034Product Flag?YSubstance Flag?Delist Request?
Patented Use:METHOD FOR TRANSDERMAL DELIVERY OF TESTOSTERONE
Patent:➤ Sign UpPatent Expiration:Feb 11, 2034Product Flag?YSubstance Flag?Delist Request?
Patented Use:METHOD FOR TRANSDERMAL DELIVERY OF TESTOSTERONE
Patent:➤ Sign UpPatent Expiration:Feb 11, 2034Product Flag?YSubstance Flag?Delist Request?
Patented Use:METHOD FOR TRANSDERMAL DELIVERY OF TESTOSTERONE

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Healthtrust
Federal Trade Commission
Fish and Richardson
Johnson and Johnson
Fuji
Baxter
Deloitte
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.